A Déjà Vu Moment: The Persistent Challenges in Women’s Health Research

By Editorial Staff
Published: November 3, 2026

The pursuit of equitable healthcare remains one of the most complex challenges in modern medicine. Despite decades of advocacy and legislative promises, the landscape of women’s health research at the federal level continues to grapple with systemic stagnation. In a recent, pointed column for the journal Nature, Alina Salganicoff, a leading voice at KFF (Kaiser Family Foundation), warns that the nation is experiencing a "déjà vu moment"—a recurring cycle where political rhetoric regarding women’s health research consistently outpaces institutional delivery.

As the United States navigates shifting federal priorities, the call for structural reform at the National Institutes of Health (NIH) has intensified. Salganicoff, who co-chaired a congressionally mandated National Academy of Sciences, Engineering and Medicine (NASEM) committee, argues that without a fundamental shift in how research is prioritized, funded, and executed, the health outcomes for women will continue to lag behind those of their male counterparts.

The Main Facts: Why History Keeps Repeating

The central premise of Salganicoff’s analysis is that "new" initiatives in women’s health often lack the teeth to enforce long-term change. Historically, administrations from both sides of the aisle have announced high-profile task forces or funding surges for women’s health. Yet, these efforts frequently lose momentum during budgetary cycles or leadership transitions.

At the heart of the issue is the NIH’s research architecture. While the Office of Research on Women’s Health (ORWH) exists to oversee and promote research on sex and gender differences, critics argue that the office lacks sufficient authority to mandate compliance across the various NIH institutes. Consequently, research on conditions that disproportionately affect women—or present differently in women—often remains underfunded or relegated to the periphery of major clinical studies.

Chronology of Reform: A Timeline of Stalled Progress

To understand the current frustration, one must look at the timeline of federal engagement with women’s health:

1990: The NIH establishes the Office of Research on Women’s Health, a landmark moment intended to ensure that women are included in clinical trials.
1993: The National Institutes of Health Revitalization Act is signed into law, legally requiring the inclusion of women and minorities in clinical research.
The Early 2000s: Despite the 1993 mandate, internal reviews indicate that while inclusion improved, the analysis of sex-based differences in data remained inconsistent.
2014-2016: The NIH introduces the "Sex as a Biological Variable" (SABV) policy, requiring researchers to account for sex in preclinical research. While seen as a win, implementation remains uneven.
2024-2025: Heightened congressional pressure leads to the formation of the NASEM committee, tasked with evaluating the efficacy of the NIH’s current research strategies.
November 2026: Alina Salganicoff’s publication in Nature highlights the committee’s findings, suggesting that the "promise" of previous decades has yet to be fully realized in clinical practice.

Supporting Data: The Disparity Gap

The necessity for reform is underscored by persistent data gaps. Despite mandates, the medical community frequently highlights the following:

Clinical Trial Enrollment: While women now make up a larger percentage of trial participants, the data is often not disaggregated by sex in a way that allows for meaningful clinical application.
Disease-Specific Funding: Conditions such as endometriosis, polycystic ovary syndrome (PCOS), and maternal mortality-related complications receive a disproportionately lower share of research dollars relative to their disease burden compared to conditions that primarily affect men.
Diagnostic Delays: Women, on average, face longer diagnostic journeys for autoimmune diseases and cardiovascular issues, largely because standard clinical models are built on historical data that prioritized male physiology.

The NASEM committee’s research indicates that the "one-size-fits-all" approach to medicine—which historically utilized male cells, animals, and human subjects as the default—remains an embedded bias in the research pipeline.

Official Responses and Institutional Perspectives

The NIH has consistently maintained that it is committed to scientific rigor and the inclusion of all populations. In response to the growing chorus of criticism, agency officials often point to the success of the All of Us research program and the expansion of the ORWH’s budget as evidence of progress.

However, the NASEM committee, co-chaired by Salganicoff, posits that "incremental growth" is not the same as "structural integration." The committee’s recommendations are bold:

Mandatory Oversight: Shifting from a collaborative advisory model to one where the ORWH has the power to withhold or redirect funding if institutes fail to meet sex-inclusion criteria.
Accountability Metrics: Implementing a public-facing dashboard that tracks not just enrollment, but the outcomes of research disaggregated by sex and gender.
Career Incentives: Ensuring that academic researchers who prioritize sex-based analysis in their studies are rewarded through the grant-review process, thereby shifting the culture of the scientific community from the ground up.

Implications: The Future of Women’s Health Policy

The implications of this "déjà vu" are profound. If the NIH fails to modernize its approach, the medical system will continue to provide suboptimal care for more than half of the population. This has direct economic consequences, as undiagnosed or poorly managed conditions in women lead to higher long-term healthcare costs and decreased workforce participation.

The Intersection of Research and Access

Beyond the laboratory, the research deficit directly impacts the information available to the public. As highlighted in recent KFF reports, women are increasingly turning to online sources to bridge the gap in clinical knowledge. When trusted institutions fail to provide robust, sex-specific medical data, women are left to navigate a minefield of misinformation regarding fertility care, reproductive health, and chronic illness management.

Moving Beyond the "Moment"

For the recommendations of the NASEM committee to move from policy documents to reality, there must be a sustained political will that transcends partisan cycles. Salganicoff’s intervention serves as a clarion call to policymakers: institutional inertia is not a neutral state. It is an active barrier to health equity.

The next decade will be a litmus test for the NIH. Will it evolve into an institution that treats sex as a fundamental biological variable in every study, or will it remain trapped in the cycle of promising reform while delivering only modest adjustments? The answer lies not in the rhetoric of the next administration, but in the specific, measurable changes made to the grant-making and oversight mechanisms that govern American science.

As the medical community looks forward, the consensus is clear: the era of "including" women in research is over; the era of "centering" women’s health must begin. Anything less will ensure that the current moment of déjà vu will only lead to the same frustration in years to come.